A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, accounting for the majority of breast cancer-related death. Due to the lack of specific therapeutic targets, chemotherapeutic agents (e.g., paclitaxel) remain the mainstay of systemic treatment, but enrich a subpop...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Sahli, Sara, Hua, Khang, Sulaiman, Andrew, Chambers, Jason, Li, Li, Farah, Eliya, McGarry, Sarah, Liu, Dan, Zheng, Peiyong, Lee, Seung-Hwan, Cui, Jiefeng, Ekker, Marc, Côté, Marceline, Alain, Tommy, Li, Xuguang, D’Costa, Vanessa M., Wang, Lisheng, Gadde, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791049/
https://www.ncbi.nlm.nih.gov/pubmed/33414428
http://dx.doi.org/10.1038/s41419-020-03308-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791049/
https://www.ncbi.nlm.nih.gov/pubmed/33414428
http://dx.doi.org/10.1038/s41419-020-03308-w

Ejemplares similares